Fibrocell announces one-for-five reverse stock split Fibrocell announced that it will effect a one-for-five reverse stock split of its common stock at 5:00 pm ET today. Beginning with the opening of trading on May 25, 2018, the Company’s common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 315721407.May 24, 2018

Celgene announces additional $3 billion share repurchase authorization Celgene announced the Company's Board of Directors authorized the repurchase of an additional $3 billion of the Company's common stock. In addition, the Company plans to enter into an accelerated share repurchase agreement to repurchase an aggregate of $2 billion of the Company's common stock. May 24, 2018

AcelRx announces FDA acceptance of NDA for DSUVIA AcelRx announced the acceptance of its NDA resubmission for DSUVIA™ by the FDA. The FDA considers the DSUVIA NDA resubmission a complete class 2 response to their Oct. 2017 action letter. Therefore, the FDA has assigned a PDUFA goal date of Nov. 3, 2018. May 24, 2018

Recro Pharma receives Complete Response Letter from the FDA Recro Pharma announced it has received a CRL from the FDA regarding the NDA for IV meloxicam. The CRL stated that although the outcome of the pivotal phase III trials demonstrated statistically significant outcomes, the FDA is unable to approve the application in its current form. May 24, 2018